Lars Bastholt
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
Papers in
- Oncology 103
- Cutaneous Melanoma Detection and Management 42
- Cancer Immunotherapy and Biomarkers 37
- CAR-T cell therapy research 22
- Cancer Treatment and Pharmacology 14
-
- Head and Neck Cancer Studies 19
- Co-authors
- Hanne Sand Hansen (13 shared papers)Lena Specht (11 shared papers)Martin Jean Schlumberger (9 shared papers)Olfred Hansen (15 shared papers)Marie Overgaard (11 shared papers)Jens Overgaard (16 shared papers)Karsten Juhl Jørgensen (9 shared papers)Steven I. Sherman (4 shared papers)
In The Last Decade
Lars Bastholt
199 papers receiving 24.7k citations
Lars Bastholt's Hit Papers
Peers
Comparison fields: 5 of 152
- Oncology 14.3k
- Immunology 6.0k
- Otorhinolaryngology 1.1k
- Endocrinology, Diabetes and Metabolism 2.5k
- Cancer Research 1.5k
Countries citing papers authored by Lars Bastholt
This map shows the geographic impact of Lars Bastholt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Bastholt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Bastholt more than expected).
Fields of papers citing papers by Lars Bastholt
This network shows the impact of papers produced by Lars Bastholt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Bastholt. The network helps show where Lars Bastholt may publish in the future.
Co-authors
The 25 scholars most cited alongside Lars Bastholt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 207 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Hit paper breakdown → | 2015 | 6916 |
| 2 | Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma Hit paper breakdown → | 2019 | 2848 |
| 3 | Tertiary lymphoid structures improve immunotherapy and survival in melanoma Hit paper breakdown → | 2020 | 1726 |
| 4 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2014 | 1292 |
| 5 | Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy Hit paper breakdown → | 2016 | 1099 |
| 6 | Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial Hit paper breakdown → | 2003 | 557 |
| 7 | A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 Hit paper breakdown → | 1998 | 487 |
| 8 | 2011 | 472 | |
| 9 | 2017 | 423 | |
| 10 | Diagnosis and treatment of basal cell carcinoma: European consensus–based interdisciplinary guidelines Hit paper breakdown → | 2019 | 414 |
| 11 | Diagnosis and treatment of Merkel Cell Carcinoma. European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 403 |
| 12 | 2008 | 402 | |
| 13 | 2016 | 391 | |
| 14 | Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline Hit paper breakdown → | 2015 | 383 |
| 15 | 2012 | 297 | |
| 16 | Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Hit paper breakdown → | 2021 | 296 |
| 17 | 2009 | 291 | |
| 18 | 2005 | 279 | |
| 19 | 2000 | 237 | |
| 20 | 2011 | 234 |
About Lars Bastholt
Lars Bastholt is a scholar working on Oncology, Otorhinolaryngology, Endocrinology, Diabetes and Metabolism, Immunology and Pulmonary and Respiratory Medicine, having authored 207 papers that have together received 25.3k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (42 papers), Cancer Immunotherapy and Biomarkers (37 papers), Thyroid Cancer Diagnosis and Treatment (29 papers), Melanoma and MAPK Pathways (29 papers), CAR-T cell therapy research (22 papers), Head and Neck Cancer Studies (19 papers), Immunotherapy and Immune Responses (17 papers) and Cancer Treatment and Pharmacology (14 papers). The work is most often cited by research in Oncology (14.3k citations), Immunology (6.0k citations), Otorhinolaryngology (1.1k citations), Endocrinology, Diabetes and Metabolism (2.5k citations) and Cancer Research (1.5k citations). Lars Bastholt has collaborated with scholars based in Denmark, France and Italy. Frequent co-authors include Hanne Sand Hansen, Lena Specht, Martin Jean Schlumberger, Olfred Hansen, Marie Overgaard, Jens Overgaard, Karsten Juhl Jørgensen, Steven I. Sherman, Barbara Jarząb and Furio Pacini. Their work appears in journals such as European Journal of Cancer, Annals of Oncology, Acta Oncologica, Melanoma Research and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.